Dr Reddy News
US generics, domestic market to drive healthy sales growth for pharma companies in Q4
Uncertainties around US tariffs and the end of the limited competition period for generic Revlimid in the US will loom in 2026.
3 min read28 Apr 2025Dr Reddy’s layoffs: Pharma major to cut workforce cost by 25%? Here’s what the drugmaker says
Dr Reddy’s layoffs: The leading pharmaceutical major has denied ‘factually incorrect’ media reports claiming it plans to cut workforce costs by 25 per cent amid a downsizing initiative.
2 min read15 Apr 2025US Tariffs on Pharma: Dr Reddy’s to Sun Pharma—can Indian drugmakers escape Trump’s tariff tantrums?
US Tariffs on Pharma: Analysts believe the key question is whether India can be exempted from the pharma tariffs, given the better relationship between the countries and the critical nature of India’s generic drug supplies to the US healthcare system.
3 min read9 Apr 2025Sun Pharma vs Dr Reddy’s vs Lupin shares: Which pharma stock to buy after Trump tariffs?
Sun Pharma share price has seen a 10% decline in year-to-date (YTD) performance and an 11% drop over the past six months. However, the stock has delivered a strong 74% return in two years and a remarkable 352% gain over five years, reflecting its long-term strength.
3 min read4 Apr 2025Will Natco and Dr. Reddy’s bet on weight-loss drug Ozempic’s copy pay off?
Natco Pharma and Dr. Reddy’s Laboratories are eyeing blockbuster drug–Novo Nordisk’s breakout star Semaglutide, sold under brand names Ozempic and Wegovy
6 min read19 Feb 2025Dr Reddy’s Laboratories share price declines 6% post Q3 results: Should you buy, sell or hold?
Stock Market Today: Dr Reddy’s Laboratories share price declined more than 6% in the morning trades on Friday post-Q3 results that were announced after the market hours of Thursday.
2 min read24 Jan 2025Dr Reddy’s Labs Q3 Results: Profit grows 2% YoY to ₹1413 crore; revenue up 16%
Dr Reddy’s Laboratories reported a 2% YoY increase in PAT to ₹1,413.3 crore for Q3 2024, driven by a 16% rise in revenue to ₹8,358.6 crore. The company invested ₹6.7 billion in R&D, focusing on complex generics and biosimilars.
1 min read23 Jan 2025Can Dr Reddy’s shrug off Revlimid’s patent expiry?
DRL also faces headwinds because of increasing competitive intensity in the generic market and exchange rate volatility.
2 min read10 Jan 2025Dr Reddy’s share price jumps 4% on Nuvama’s upgrade to buy; brokerage sees potential despite risks from Revlimid expiry
Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ₹1,553, highlighting proactive strategies to mitigate the impact of Revlimid’s patent expiration in 2026, despite a 9.35% drop in net profit for September 2024.
2 min read8 Jan 2025Buy or sell: Sumeet Bagadia recommends three stocks to buy on Monday — 30 December 2024
Buy or sell: Sumeet Bagadia recommends three stocks to buy on Monday — Can Fin Homes, Dr Reddy’s Laboratories, and Mahindra & Mahindra
4 min read28 Dec 2024Popular Topics
Budget
The Union Budget contains details about the estimated receipts and the expenditure of the government for a particular fiscal year. The Budget is allotted for the upcoming fiscal year, which runs from 1st April to 31st March of the next year. Here is a quick guide on how the Union Budget is prepared